Next Article in Journal
Protective and Recovery Effects of Resveratrol Supplementation on Exercise Performance and Muscle Damage following Acute Plyometric Exercise
Previous Article in Journal
Dietary Supplement Enriched in Antioxidants and Omega-3 Promotes Glutamine Synthesis in Müller Cells: A Key Process against Oxidative Stress in Retina
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 13
Issue 9
10.3390/nu13093218
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Impact of Nutritional Assessment on the Clinical Outcomes of Patients with Non-albicans Candidemia: A Multicenter Study

by
Yi-Chien Lee
1,2,
Yong-Chen Chen
2,3,
Jann-Tay Wang
4,5,
Fu-Der Wang
6,7,
Min-Han Hsieh
8,
Ing-Moi Hii
9,
Yu-Lin Lee
9,
Mao-Wang Ho
10,
Chun-Eng Liu
9,
Yen-Hsu Chen
8 and
Wei-Lun Liu
2,11,*
1
Department of Internal Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City 243, Taiwan
2
School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City 242, Taiwan
3
Master Program of Big Data in Biomedicine, College of Medicine, Fu Jen Catholic University, New Taipei City 242, Taiwan
4
Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan
5
Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tsu-Nan County 350, Taiwan
6
Division of Infectious Diseases, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan
7
School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
8
Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
9
Division of Infectious Diseases, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan
10
Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan
11
Division of Critical Care Medicine, Department of Emergency & Critical Care Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City 243, Taiwan
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Nutrients 2021, 13(9), 3218; https://doi.org/10.3390/nu13093218
Submission received: 14 August 2021 / Revised: 11 September 2021 / Accepted: 14 September 2021 / Published: 16 September 2021
(This article belongs to the Section Clinical Nutrition)
Browse Figures
Review Reports Versions Notes

Abstract

:
Several studies have demonstrated that malnutrition is a negative prognostic factor for clinical outcomes. However, there is limited evidence for the effect of malnutrition on clinical outcomes in patients with candidemia. We investigated the relationship between malnutrition and all-cause 28-day mortality among patients with non-albicans candidemia. Between July 2011 and June 2014, all adult patients with non-albicans candidemia, including C. tropicalis, C. glabrata, C. parapsilosis and so on, were enrolled. The Malnutrition Universal Screening Tool (MUST) scores were used to determine the patients’ nutritional status before the onset of candidemia. A total of 378 patients were enrolled; 43.4% developed septic shock and 57.1% had a high risk of malnutrition (MUST ≥ 2). The all-cause 28-day mortality rate was 40.7%. The Cox proportional hazards model revealed that C. tropicalis (HR, 2.01; 95% CI, 1.24–3.26; p = 0.005), Charlson comorbidity index (HR, 1.10; 95% CI, 1.03–1.18; p = 0.007), Foley catheter use (HR, 1.68; 95% CI, 1.21–1.35; p = 0.002), concomitant bacterial infections (HR, 1.55; 95% CI, 1.11–2.17; p = 0.010), low platelet count (HR, 3.81; 95% CI, 2.45–5.91; p < 0.001), not receiving antifungals initially (HR, 4.73; 95% CI, 3.07–7.29; p < 0.001), and MUST ≥ 2 (HR, 1.54; 95% CI, 1.09–2.17; p = 0.014) were independently associated with all-cause 28-day mortality. A simple screening tool for nutritional assessment should be used for patients with non-albicans candidemia to detect early clinical deterioration, and a tailored nutritional care plan should be established for malnourished individuals, to improve their clinical outcomes.

1. Introduction

Candida, one of the most frequently encountered invasive fungal infections in humans, causes a wide spectrum of clinical manifestations, including candidemia, intra-abdominal infections, and osteomyelitis [1]. Candidemia usually leads to longer hospital stay, increased medical costs, substantial complications, and all-cause in-hospital mortality of up to 30–60% [2,3]. Candida albicans remains the leading cause of candidemia, but non-albicans candidemia has progressively increased worldwide in recent years, with a varying distribution of species between different countries, particularly in the Asia-Pacific regions [4,5,6]. Due to the high mortality rate of patients with candidemia, the presence of septic shock [7,8,9,10,11,12], need for mechanical ventilation [7], severe underlying diseases [7,11], multiple organ failure [8], aging [11], concomitant bacterial infections [12], and inappropriate initiation of antifungal agents [9] were found to be independent risk factors associated with mortality in various studies. Furthermore, different fatality rates have been observed based on different Candida species, and it seems that patients with non-albicans candidemia have a worse prognosis [13].
Universally, malnutrition is a key topic: its prevalence is as high as 37.8–78.1% in critically ill patients [14], and around 20–50% of hospitalized patients are diagnosed with undernutrition upon admission [15]. Several prior studies have validated the association between poor nutritional status and adverse clinical outcomes among patients receiving intensive care [14,15,16,17], particularly those with candidemia [18]. Different nutrition assessment and screening tools have been used in the previous studies, including Subjective Global Assessment [19], Mini Nutritional Assessment [20], Nutrition Risk Screening-2002 (NRS-2002) [21], and Malnutrition Universal Screening Tool (MUST) [22]. MUST, the foundation for the NRS-2002, was established to recognize individuals with malnourishment in all healthcare settings. It had three components: calculation of the body mass index (BMI) as well as recording of the percentage of unintentional weight loss in the past months and the presence of acute sickness with a reduction in nutritional intake for days [22]. Limited research has been done on the influence of malnourishment on the clinical outcomes of patients with non-albicans candidemia. This study aimed to compare the clinical characteristics of non-albicans candidemic patients with a high risk of malnutrition to those of patients without a high risk and antifungal susceptibility, and to identify the predictors of all-cause 28-day mortality among patients with non-albicans candidemia.

2. Materials and Methods

2.1. Study Design and Settings

We conducted a retrospective multicenter observational study at five tertiary hospitals, including Taipei Veterans General Hospital in northern Taiwan, China Medical University Hospital and Changhua Christian Hospital in central Taiwan, Chi Mei Medical Center, Liouying Branch, and Kaohsiung Medical University Hospital in southern Taiwan, between 1 July 2011 and 30 June 2014. All adult patients aged over 20years with positive blood cultures for non-albicans Candida species admitted to any of the five participating hospitals were eligible for enrollment. Only the first episode of non-albicans candidemia was analyzed in patients who developed two or more episodes of candidemia during the study period. Individuals with two or more non-albicans Candida species isolated from blood cultures were excluded. A standardized case report form was used to collect information on the demographics and clinical characteristics, including the age, sex, source of candidemia, Charlson comorbidity index, risk factors (receiving chemotherapy, total parenteral nutrition (TPN), use of central venous catheters, recent abdominal surgery, steroids), disease severity (septic shock and receiving intensive care), concomitant bacterial infections, laboratory data, BMI, initial antifungal treatment, and 28-day mortality. The study was approved by the medical ethics committees of the five participating hospitals, and all clinical investigations were performed following the guidelines of the Declaration of Helsinki.

2.2. Definitions

Candidemia was confirmed by the isolation of non-albicans Candida species in at least one set of blood cultures among patients with corresponding clinical symptoms/signs of infection [23]. The origin of the candidemia was determined based on clinical manifestations, microbiological findings, and radiological investigations. Catheter-related bloodstream infection (CRBSI) was defined by the same organism being isolated from the indwelling catheter segment with the growth of ≥15 colony-forming units via semi-quantitative tip culture and peripheral blood culture [24]. If no apparent focus of the infection was identified at other sites, candidemia was classified as primary [23]. Septic shock was diagnosed when a patient had either systolic blood pressure ≤ 90 mmHg or mean arterial pressure ≤ 70 mmHg accompanied by the use of vasopressors. A concomitant bacterial infection was defined as a bacterial infection occurring within seven days prior to the first episode of the candidemia. Use of steroids was defined as a prescription of at least 10 mg prednisolone or an equivalent daily dosage for more than one week within 30 days before candidemia [25]. The initial antifungal treatment was the first prescribed antifungal agent, while invasive fungemia was clinically suspected. All-cause 28-day mortality was recorded when a patient died from any cause during hospitalization.

2.3. Mycological Diagnosis of Candidemia and Antifungal Susceptibility Testing

Fungal blood cultures were processed using the BACTEC culture system (Becton Dickinson Microbiology System, Sparks, MD, USA). All non-albicans Candida isolates were identified to the species level by morphology analysis on CHROMagar (Creative Life Science, Ltd., New Taipei City, Taiwan) and biochemical methods using the API ID 32C system (bioMérieux, Marcy l’Etoile, France) or Vitek 2 system (bioMérieux, Marcy l’Etoile, France) according to the regulations of each participating hospital. The in vitro susceptibility to nine antifungal agents, including anidulafungin, caspofungin, micafungin, fluconazole, voriconazole, itraconazole, posaconazole, 5-fluocytosine, and amphotericin B, was determined using the broth microdilution method with the Sensititre YeastOne system (Trek Diagnostic Systems, Ltd., East Grinstead, UK) according to the manufacturer’s instructions. We utilized C. krusei (ATCC 6258) and C. parapsilosis (ATCC 22019) as reference isolates for quality control. The minimal inhibitory concentrations (MICs) of the nine tested antifungal agents were interpreted using the clinical breakpoints or epidemiological cut-off values proposed by the Clinical and Laboratory Standard Institute (CLSI) recommendations [26].

2.4. Nutrition Assessment

All patients with non-albicans candidemia underwent nutritional assessment via measurement of MUST scores before the onset of candidemia. The information needed for the MUST was provided by either the patients or their caregivers. As described before, the MUST methodology comprised three independent parameters: BMI score (BMI > 20 = 0, BMI 18.5–20 = 1, BMI < 18.5 = 2); percentage of unexpected weight loss in the past 3–6 months (weight loss < 5% = 0, weight loss 5–10% = 1, weight loss > 10% = 2); acute disease effect score (a score of 2 was added if the patient was acutely ill with subsequent lack of any dietary intake for more than five days). Based on the total scores calculated, the development of malnourishment was determined as low (total score = 0), medium (total score = 1), and high risk (total scores ≥ 2). We further classified MUST into a dichotomized group (low to medium risk of malnutrition 0 or 1 (non-high-risk group), versus high risk of malnutrition ≥ 2 (high-risk group)). The MUST score was selected as the evaluation tool for this study because of its good predictive value for clinical outcomes in a variety of patient populations [27,28,29].

2.5. Statistical Analyses

Descriptive data for quantitative variables were expressed as mean ± standard deviation and analyzed using Student’s t-test or Mann–Whitney U test. Categorical variables were presented as counts (%) and compared using the chi-squared test or Fisher’s exact test. Statistical significance was determined using two-tailed tests, and a p-value < 0.05 was considered as the threshold for statistical significance. To identify the independent predictors of all-cause 28-day mortality, a Cox proportional hazards model in a stepwise approach was used to calculate the hazard ratios and corresponding 95% confidence intervals. Survival was plotted using Kaplan–Meier curves, and differences were evaluated using the log-rank test. All statistical analyses were conducted using SAS statistical software (version 9.4; SAS Institute, Cary, NC, USA).

3. Results

Initially, 597 patients with a diagnosis of non-albicans candidemia were recruited, but 219 patients were excluded because of missing clinical data, including 205 with incomplete MUST scores, 12 with incorrect sampling, and two that were transferred to another hospital. Finally, 378 patients were enrolled in this study, and 146 (38.6%) were infected with C. tropicalis, 133 (35.2%) with C. glabrata, 78 (20.6%) with C. parapsilosis, 21 (5.6%) with other Candida species, including C. guilliermondii (8, 2.1%), C. krusei (4, 1.1%), C. lusitaniae (2, 0.5%), C. lipolytica (2, 0.5%), C. intermedia (1, 0.3%), C. catenulate (1, 0.3%), C. metapsilosis (1, 0.3%), C. pulcherrima (1, 0.3%), and C. sake (1, 0.3%) (Figure 1).
Among these patients, more than 60% were men, and their mean ± standard deviation of age was 66 ± 17 years (Table 1). The three leading origins of candidemia were the central venous catheter, primary infection, and an intra-abdominal focus. The predominant non-albicans Candida species was C. tropicalis (38.6%). More than two-fifths (43.4%) of the patients developed septic shock due to candidemia, and the mean ± standard deviation of the Charlson comorbidity score was 4.2 ± 2.5. Previous use of steroids was the most common precipitating factor associated with non-albicans candidemia, and approximately half (47.4%) of all the patients were found to have concomitant bacterial infections. The majority (71.2%) of the participants were prescribed fluconazole initially, and the all-cause 28-day mortality rate in this study was 40.7%.
The in vitro susceptibilities of the 304 non-albicans Candida isolates to the nine tested antifungal agents are summarized in Table 2. All three echinocandins exhibited excellent sensitivity against these strains (>95%), except for caspofungin against C. glabrata isolates (91.8%), indicating that echinocandins remain the drug of choice for treating non-albicans candidemia. However, the echinocandin MIC50 and MIC90 of C. parapsilosis (0.5–1 and 0.5–2 mg/L, respectively) were higher than those of the other non-albicans Candida species. The overall fluconazole-resistance rate among all non-albicans Candida isolates was 10.2% (31), including 25 in C. tropicalis, four in C. glabrata, and two in C. parapsilosis. Moreover, C. glabrata displayed higher fluconazole MIC50 and MIC90 (16 mg/L and 32 mg/L, respectively), and the highest resistance rate to fluconazole was observed in C. tropicalis (17.1%). The voriconazole-resistance rates in C. tropicalis and C. parapsilosis were 15.1% and 2.1%, respectively.
The comparisons of the demographics, laboratory data, and clinical outcomes between the high-risk and non-high-risk groups are also illustrated in Table 1. Half of the patients (57.1%) belonged to the group with a high risk of malnutrition, and the mean age and sex distribution were not different between the two groups. More primary candidemia and catheter-associated sources were found in the non-high-risk group, but the focus of candidemia being the urinary tract, respiratory tract, and intra-abdominal region was more frequently observed in the high-risk group. The patients who acquired infections caused by the three predominant types of the non-albicans Candida species were significantly different between the two groups. A higher proportion of patients in the high-risk group presented with septic shock (65.4% vs. 35.8%, p = 0.01), but the Charlson comorbidity index score was similar between the two groups. As for the risk factors related to candidemia, only TPN use was much more commonly encountered in high-risk patients, with significant differences. Furthermore, patients at high risk for malnutrition tended to have concomitant bacterial infections. Laboratory parameters did not differ between the two groups, except for a higher platelet count observed in the high-risk group. ICU admission and all-cause 28-day mortality were not different between the two groups, although a slightly higher percentage of patients at high risk for malnutrition died than that of the non-high-risk patients, without a significant difference (59.9% vs. 35.2%, p = 0.06). We further explored the 28-day survival probability of high-risk versus non-high-risk patients acquiring non-albicans candidemia, and there was a trend that the former had a higher mortality rate when compared to the latter, as shown in Figure 2 (p = 0.08).
To verify the importance of nutrition assessment on the clinical outcomes of patients with non-albicans candidemia, a Cox proportional hazards model in a stepwise approach was performed using specific identified factors (Table 3). The source of the candidemia, C. tropicalis, Candida colonization, Foley catheter use, concomitant bacterial infections, lower haemoglobin level, thrombocytopenia, ICU admission, septic shock, and no antifungal therapy initially were all associated with all-cause 28-day mortality in patients with non-albicans candidemia. After adjustment for confounders, C. tropicalis (HR, 2.01; 95% CI, 1.24–3.26; p = 0.005), Charlson comorbidity index (HR, 1.10; 95% CI, 1.03–1.18; p = 0.007), Foley catheter use (HR, 1.68; 95% CI, 1.21–1.35; p = 0.002), concomitant bacterial infections (HR, 1.55; 95% CI, 1.11–2.17; p = 0.010), low platelet count (HR, 3.81; 95% CI, 2.45–5.91; p < 0.001), not receiving antifungals initially (HR, 4.73; 95% CI, 3.07–7.29; p < 0.001), and MUST ≥ 2 (HR, 1.54; 95% CI, 1.09–2.17; p = 0.014) were recognized as independent predictors of a higher risk of all-cause 28-day mortality.

4. Discussion

An increasing number of studies have demonstrated that non-albicans Candida has played an increasingly clinical role in the recent decades [4,5,6,30,31]. Additionally, malnutrition might predict a poorer prognosis in critically ill patients, including patients with candidemia [18]. To the best of our knowledge, this is the first study to authenticate the risk factors for all-cause 28-day mortality among non-albicans candidemic individuals and the impact of undernutrition on clinical outcomes. In the present study, the majority of the non-albicans Candida species were C. tropicalis, and 43.4% of the patients developed septic shock with an all-cause 28-day mortality rate of 40.7%. Echinocandins retained their excellent in vitro susceptibility against non-albicans Candida isolates, and the overall fluconazole-resistance rate was approximately 10%. More than 50% of the candidemic patients were classified as having a high risk of malnutrition, and the independent predictors of all-cause 28-day mortality were C. tropicalis, Charlson comorbidity index, Foley catheter use, concomitant bacterial infections, low platelet count, no antifungal use initially and MUST ≥ 2.
Most recent studies have mainly analyzed the predictors of mortality in candidemic patients with secondary results regarding the incidence of septic shock, which ranged from 21.2 to 49.3% in candidemic individuals due to all Candida species [10,12,32,33], and 28.6–31.6% among patients with non-albicans Candida bloodstream infections [33,34,35]. However, a much higher prevalence of septic shock (43.4%) was observed in our study, probably because more patients with C. tropicalis candidemia were enrolled, which was supported by Ko et al.’s proposal [36]. Additionally, the overall fluconazole-resistance rate and in vitro susceptibility rate of echinocandins against non-albicans Candida isolates were, 3.4–8.8% [1,12,37] and 97.6–100% [1,37], respectively, comparable to our findings. Regarding the clinical outcomes, a few recent reports illustrated in-hospital mortality rates of approximately 44.6–60.0% [7,32,38], similar to our results, implicating a poor prognosis in patients with non-albicans Candida bloodstream infections.
As previously reported, patients with fumgemia due to C. tropicalis might have a higher mortality rate than those with fungemia due to other Candida species [39,40]. Additionally, the significant association of C. tropicalis with poor clinical outcomes has been validated [36], which is consistent with our findings. Possible explanations for the virulence mechanisms of C. tropicalis, including its adhesion behavior, biofilm formation, hemolysis activity, secretion of enzymes, and dissemination potential [41], have been elucidated, and prominent resistance to azoles by C. tropicalis affecting the initiation of the appropriate antifungals might be another reason from our study. Therefore, clinicians should be aware of the care of patients with C. tropicalis fungemia.
Patient-related factors, such as comorbid conditions and a poor prognosis, are highly relevant among individuals with Candida bloodstream infections. Notably, the Charlson comorbidity index, a comorbidity measure useful for predicting mortality risk, has been demonstrated in several studies [11,42], comparable to our results. Likewise, indwelling urinary catheters as a risk factor for mortality among candidemic patients in our study has also been previously illustrated [43,44]: predisposition to urinary tract infections and formation of biofilms on the surface of catheters lowering the efficacy of antifungals resulted in patients being more susceptible to death. Subsequently, detailed calculation of the Charlson comorbidity index and early removal of unnecessary urinary catheters would aid healthcare workers in handling the clinical outcomes of non-albicans candidemia cases.
The role of concurrent bacterial infections on in-hospital mortality in patients with candidemia has been established in previous reports [12,45], similar to our results. It was anticipated that concomitant bacterial infections would lead to candidemic patients being vulnerable to severe sepsis or septic shock and eventually increase the risk of mortality; therefore, effective antimicrobial agents against concurrent bacterial infections should be initiated aggressively to improve the clinical prognosis. Moreover, thrombocytopenia has been proposed as implicating candidemic patients with more seriously ill conditions and at high risk of mortality [46]. The adverse effects of low platelets on patients’ outcomes in response to fungal infection [12] and the key role of platelets in inflammation, immunity, and infectious diseases [47] might be the causes. Nevertheless, the molecular mechanisms of thrombocytopenia and platelet function in non-albicans candidemia should be further studied. Undoubtedly, early administration and appropriate initiation of antifungal agents for fungemic patients will lead to a better prognosis [9,48] than if no antifungals are initiated for these patients from the start, similar to our findings. Consequently, empirical or preemptive antifungal therapy should be considered prudently when clinicians are highly suspicious of non-albicans candidemia.
To the best of our knowledge, no previous research has explored the relationship between malnutrition and clinical outcomes in patients with non-albicans candidemia. Nutritional deficiencies are linked to a higher risk of infections and mortality from bloodstream infections [49]. A few studies have demonstrated that malnutrition predisposes acutely ill patients to acquiring infections [14], probably due to the persistent inflammation and immune dysfunction associated with undernutrition [50], and eventually, there can be progression to severe sepsis, septic shock, and death. Hence, poor nutritional status as an independent factor for all-cause 28-day mortality in patients with non-albicans candidemia is reasonable. Malnutrition is a modifiable factor: its early identification and correction among patients at high-risk might prevent its potential deleterious effects, even though there are no internationally standardized screening tools for the assessment of nutritional status [51]. MUST has been validated to predict the risk of malnutrition with the highest sensitivity and hazard ratio of mortality by Rabito et al. [27], which was similar to our results. Furthermore, non-albicans fungemic individuals within the high-risk group tended to have a higher mortality rate via the Kaplan–Meier method. Therefore, routine nutrition screening for all hospitalized patients, particularly those with non-albicans candidemia, not only predicted the risk of all-cause 28-day mortality but also established an adequate nutritional care plan tailored to these malnourished individuals to lower complication rates.
There were some limitations to our study. First, it was conducted retrospectively; therefore, unavoidable bias and missing data are anticipated. Second, there could have been trivial variations in the collection of MUST data because this was a multicenter study, and measurement of weight loss percentage was probably a barrier during clinical practice. Finally, serum levels of some inflammatory mediators, such as interleukin-6 or interleukin-10, were not tested in our study, and how inflammatory cytokines in malnutrition patients with non-albicans candidemia played a role in the risk of mortality requires further investigation.

5. Conclusions

Our study revealed that a high risk of malnourishment, that is, MUST ≥ 2, is independently associated with a higher risk of all-cause 28-day mortality in non-albicans candidemic patients. A simple and rapid screening tool for malnutrition risk, such as MUST, can help physicians recognize malnourished individuals, and early goal-directed therapy for high-risk patients can be achieved as soon as possible. Furthermore, because malnutrition remains a reversible and treatable condition, an optimal nutritional care strategy should be implemented appropriately to improve patients’ prognosis.

Author Contributions

Conceptualization, Y.-C.L., F.-D.W. and W.-L.L.; methodology, Y.-C.C., J.-T.W. and W.-L.L.; validation, Y.-C.L., Y.-C.C. and W.-L.L.; formal analysis Y.-C.C. and J.-T.W.; investigation, M.-H.H., I.-M.H., Y.-L.L., M.-W.H., C.-E.L. and Y.-H.C.; resources, F.-D.W., M.-H.H., I.-M.H. and M.-W.H.; data curation, F.-D.W., Y.-L.L., C.-E.L. and Y.-H.C.; writing—original draft preparation, Y.-C.L., J.-T.W. and W.-L.L.; writing—review and editing, Y.-C.L., Y.-C.C. and W.-L.L.; visualization, J.-T.W., F.-D.W. and W.-L.L.; supervision, Y.-C.L., Y.-C.C., J.-T.W. and W.-L.L.; project administration, W.-L.L. All authors participated in the study design, revised the manuscript, and approved the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

There were no external or internal sources of specific funding for this paper, and the data were generated as part of the department’s routine work.

Institutional Review Board Statement

This study was conducted based on the principles of the Declaration of Helsinki and approved by the medical ethics committees of the five participating hospitals.

Informed Consent Statement

Informed consent was not required due to the observational study design without attempting to change the standard of care.

Data Availability Statement

The datasets used during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declared no conflict of interest.

References

  1. Toda, M.; Williams, S.R.; Berkow, E.L.; Farley, M.M.; Harrison, L.H.; Bonner, L.; Marceaux, K.M.; Hollick, R.; Zhang, A.Y.; Schaffner, W.; et al. Population-Based Active Surveillance for Culture-Confirmed Candidemia Four Sites, United States, 2012–2016. MMWR Surveill. Summ. 2019, 68, 1–15. [Google Scholar] [CrossRef] [PubMed]
  2. Cleveland, A.A.; Farley, M.M.; Harrison, L.H.; Stein, B.; Hollick, R.; Lockhart, S.R.; Magill, S.S.; Derado, G.; Park, B.J.; Chiller, T.M. Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008–2011. Clin. Infect. Dis. 2012, 55, 1352–1361. [Google Scholar] [CrossRef] [PubMed]
  3. Bassetti, M.; Taramasso, L.; Nicco, E.; Molinari, M.P.; Mussap, M.; Viscoli, C. Epidemiology, species distribution, antifungal sus-ceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS ONE 2011, 6, e24198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Guinea, J.; Zaragoza, O.; Escribano, P.; Mazuelos, E.M.; Pemán, J.; Sanchez-Reus, F.; Cuenca-Estrella, M. Molecular Identification and Antifungal Susceptibility of Yeast Isolates Causing Fungemia Collected in a Population-Based Study in Spain in 2010 and 2011. Antimicrob. Agents Chemother. 2013, 58, 1529–1537. [Google Scholar] [CrossRef] [Green Version]
  5. Tan, T.Y.; Hsu, L.Y.; Alejandria, M.M.; Chaiwarith, R.; Chinniah, T.; Chayakulkeeree, M.; Choudhury, S.; Chen, Y.H.; Shin, J.H.; Kiratisin, P.; et al. Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region. Med. Mycol. 2016, 54, 471–477. [Google Scholar] [CrossRef] [Green Version]
  6. Barchiesi, F.; The Candidemia Study Group; Orsetti, E.; Gesuita, R.; Skrami, E.; Manso, E. Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014. Infection 2015, 44, 205–213. [Google Scholar] [CrossRef]
  7. Ghrenassia, E.; Mokart, D.; Mayaux, J.; Demoule, A.; Rezine, I.; Kerhuel, L.; Calvet, L.; De Jong, A.; Azoulay, E.; Darmon, M. Candidemia in critically ill immunocompromised patients: Report of a retrospective multicenter cohort study. Ann. Intensiv. Care 2019, 9, 1–10. [Google Scholar] [CrossRef] [Green Version]
  8. Barchiesi, F.; Orsetti, E.; Mazzanti, S.; Trave, F.; Salvi, A.; Nitti, C.; Manso, E. Candidemia in the elderly: What does it change? PLoS ONE 2017, 12, e0176576. [Google Scholar] [CrossRef] [Green Version]
  9. Bassetti, M.; Peghin, M.; Carnelutti, A.; Righi, E.; Merelli, M.; Ansaldi, F.; Trucchi, C.; Alicino, C.; Sartor, A.; Toniutto, P.; et al. Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: A multicenter study. Intensiv. Care Med. 2017, 43, 509–518. [Google Scholar] [CrossRef]
  10. Sbrana, F.; Sozio, E.; Bassetti, M.; Ripoli, A.; Pieralli, F.; Azzini, A.M.; Morettini, A.; Nozzoli, C.; Merelli, M.; Rizzardo, S.; et al. Independent risk factors for mortality in critically ill patients with candidemia on Italian Internal Medicine Wards. Intern. Emerg. Med. 2018, 13, 199–204. [Google Scholar] [CrossRef]
  11. Luzzati, R.; Merelli, M.; Ansaldi, F.; Rosin, C.; Azzini, A.; Cavinato, S.; Brugnaro, P.; Vedovelli, C.; Cattelan, A.; Marina, B.; et al. Nosocomial candidemia in patients admitted to medicine wards compared to other wards: A multicentre study. Infection 2016, 44, 747–755. [Google Scholar] [CrossRef]
  12. Jia, X.; Li, C.; Cao, J.; Wu, X.; Zhang, L. Clinical characteristics and predictors of mortality in patients with candidemia: A six-year retrospective study. Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 1717–1724. [Google Scholar] [CrossRef] [PubMed]
  13. Ngamchokwathana, C.; Chongtrakool, P.; Waesamaae, A.; Chayakulkeeree, M. Risk Factors and Outcomes of Non-albicans Candida Bloodstream Infection in Patients with Candidemia at Siriraj Hospital—Thailand’s Largest National Tertiary Referral Hospital. J. Fungi 2021, 7, 269. [Google Scholar] [CrossRef] [PubMed]
  14. Lew, C.C.H.; Yandell, R.; Fraser, R.J.L.; Chua, A.P.; Chong, M.F.F.; Miller, M. Association Between Malnutrition and Clinical Outcomes in the Intensive Care Unit: A Systematic Review. J. Parenter. Enter. Nutr. 2016, 41, 744–758. [Google Scholar] [CrossRef] [PubMed]
  15. Sorensen, J.; Kondrup, J.; Prokopowicz, J.; Schiesser, M.; Krähenbühl, L.; Meier, R.; Liberda, M. EuroOOPS: An international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. Clin. Nutr. 2008, 27, 340–349. [Google Scholar] [CrossRef] [PubMed]
  16. Lew, C.C.H.; Wong, G.J.Y.; Cheung, K.P.; Chua, A.P.; Chong, M.F.F.; Miller, M. Association between Malnutrition and 28-Day Mortality and Intensive Care Length-of-Stay in the Critically ill: A Prospective Cohort Study. Nutrients 2017, 10, 10. [Google Scholar] [CrossRef] [Green Version]
  17. Lim, S.L.; Ong, K.C.B.; Chan, Y.H.; Loke, W.C.; Ferguson, M.; Daniels, L. Malnutrition and its impact on cost of hospitalization, length of stay, readmission and 3-year mortality. Clin. Nutr. 2012, 31, 345–350. [Google Scholar] [CrossRef] [Green Version]
  18. Piazza, O.; Boccia, M.C.; Iasiello, A.; Storti, M.P.; Tufano, R.; Triassi, M. Candidemia in Intensive Care patients. Risk factors and mortality. Minerva Anestesiol. 2004, 70, 63–69. [Google Scholar]
  19. Detsky, A.S.; McLaughlin, J.R.; Baker, J.P.; Johnston, N.; Whittaker, S.; Mendelson, R.A.; Jeejeebhoy, K.N. What is subjective global assessment of nutritional status? J. Parenter. Enteral Nutr. 1987, 11, 8–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Guigoz, Y.; Vellas, B.; Garry, P.J. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr. Rev. 1996, 54, S59–S65. [Google Scholar] [CrossRef]
  21. Kondrup, J.; Rasmussen, H.H.; Hamberg, O.; Stanga, Z.; Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): A new method based on an analysis of controlled clinical trials. Clin. Nutr. 2003, 22, 321–336. [Google Scholar] [CrossRef]
  22. Elia, M. The ‘Must’ Report. Nutritional Screening for Adults: A Multidisciplinary Responsibility. Development and Use of the‘Malnutrition Universal Screening Tool’ (Must) for Adults; BAPEN: Redditch, UK, 2003. [Google Scholar]
  23. Tang, H.-J.; Liu, W.-L.; Lin, H.-L.; Lai, C.-C. Epidemiology and Prognostic Factors of Candidemia in Cancer Patients. PLoS ONE 2014, 9, e99103. [Google Scholar] [CrossRef] [Green Version]
  24. Chen, L.-Y.; Kuo, S.-C.; Wu, H.-S.; Yang, S.-P.; Chan, Y.-J.; Chen, L.-K.; Wang, F.-D. Associated clinical characteristics of patients with candidemia among different Candida species. J. Microbiol. Immunol. Infect. 2013, 46, 463–468. [Google Scholar] [CrossRef] [Green Version]
  25. Wu, P.F.; Liu, W.L.; Hsieh, M.H.; Hii, I.M.; Lee, Y.L.; Lin, Y.T.; Ho, M.W.; Liu, C.E.; Chen, Y.H.; Wang, F.D. Epidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients. Emerg. Microbes Infect. 2017, 6, e87. [Google Scholar] [CrossRef] [Green Version]
  26. Clinical and Laboratory Standard Institute (CLSI). Performance Standards for Antifungal Susceptibility Testing of Yeast, 1st ed.; CLSI supplement M60; Clinical and Laboratory Standard Institute: Wayne, PA, USA, 2017. [Google Scholar]
  27. Rabito, E.I.; Marcadenti, A.; Fink, J.D.S.; Figueira, L.; Silva, F.M. Nutritional Risk Screening 2002, Short Nutritional Assessment Questionnaire, Malnutrition Screening Tool, and Malnutrition Universal Screening Tool Are Good Predictors of Nutrition Risk in an Emergency Service. Nutr. Clin. Pr. 2017, 32, 526–532. [Google Scholar] [CrossRef] [PubMed]
  28. Almasaudi, A.S.; McSorley, S.T.; Dolan, R.D.; Edwards, C.A.; McMillan, D.C. The relation between Malnutrition Universal Screening Tool (MUST), computed tomography–derived body composition, systemic inflammation, and clinical outcomes in patients undergoing surgery for colorectal cancer. Am. J. Clin. Nutr. 2019, 110, 1327–1334. [Google Scholar] [CrossRef] [PubMed]
  29. Sremanakova, J.; Burden, S.; Kama, Y.; Gittins, M.; Lal, S.; Smith, C.J.; Hamdy, S. An Observational Cohort Study Investigating Risk of Malnutrition Using the Malnutrition Universal Screening Tool in Patients with Stroke. J. Stroke Cerebrovasc. Dis. 2019, 28, 104405. [Google Scholar] [CrossRef] [PubMed]
  30. Guinea, J. Global trends in the distribution of Candida species causing candidemia. Clin. Microbiol. Infect. 2014, 20 (Suppl. 6), 5–10. [Google Scholar] [CrossRef] [Green Version]
  31. Kakeya, H.; Yamada, K.; Kaneko, Y.; Yanagihara, K.; Tateda, K.; Maesaki, S.; Takesue, Y.; Tomono, K.; Kadota, J.-I.; Kaku, M.; et al. National Trends in the Distribution of Candida Species Causing Candidemia in Japan from 2003 to 2014. Med. Mycol. J. 2018, 59, E19–E22. [Google Scholar] [CrossRef] [Green Version]
  32. Ortega-Loubon, C.; Cano-Hernández, B.; Poves-Alvarez, R.; Muñoz-Moreno, M.F.; Román-García, P.; Balbás-Alvarez, S.; de la Varga-Martínez, O.; Gómez-Sánchez, E.; Gómez-Pesquera, E.; Lorenzo-López, M.; et al. The Overlooked Immune State in Candidemia: A Risk Factor for Mortality. J. Clin. Med. 2019, 8, 1512. [Google Scholar] [CrossRef] [Green Version]
  33. Bassetti, M.; Vena, A.; Meroi, M.; Cardozo, C.; Cuervo, G.; Giacobbe, D.R.; Salavert, M.; Merino, P.; Gioia, F.; Fernández-Ruiz, M.; et al. Factors associated with the development of septic shock in patients with candidemia: A post hoc analysis from two pro-spective cohorts. Crit. Care 2020, 24, 117. [Google Scholar] [CrossRef] [Green Version]
  34. Chen, C.-Y.; Sheng, W.-H.; Huang, S.-Y.; Chou, W.-C.; Yao, M.; Tang, J.-L.; Tsay, W.; Tien, H.-F.; Hsueh, P.-R. Clinical characteristics and treatment outcomes of patients with candidaemia due to Candida parapsilosis sensu lato species at a medical centre in Taiwan, 2000–2012. J. Antimicrob. Chemother. 2015, 70, 1531–1538. [Google Scholar] [CrossRef] [Green Version]
  35. Puig-Asensio, M.; Padilla, B.; Garnacho-Montero, J.; Zaragoza, O.; Aguado, J.M.; Zaragoza, R.; Montejo, M.; Muñoz, P.; Ruiz-Camps, I.; Cuenca-Estrella, M.; et al. Epidemiology and predictive factors for early and late mortality in Candida blood-stream infections: A population-based surveillance in Spain. Clin. Microbiol. Infect. 2014, 20, O245–O254. [Google Scholar] [CrossRef] [Green Version]
  36. Ko, J.-H.; Jung, D.S.; Lee, J.Y.; Kim, H.A.; Ryu, S.Y.; Jung, S.-I.; Joo, E.-J.; Cheon, S.; Kim, Y.-S.; Kim, S.-W.; et al. Poor prognosis of Candida tropicalis among non-albicans candidemia: A retrospective multicenter cohort study, Korea. Diagn. Microbiol. Infect. Dis. 2019, 95, 195–200. [Google Scholar] [CrossRef] [PubMed]
  37. Khan, Z.; Ahmad, S.; Al-Sweih, N.; Mokaddas, E.; Al-Banwan, K.; Alfouzan, W.; Al-Obaid, I.; Al-Obaid, K.; Asadzadeh, M.; Jeragh, A.; et al. Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait. PLoS ONE 2019, 14, e0216250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Yeşilkaya, A.; Azap, Ö.; Aydın, M.; Ok, M.A. Epidemiology, species distribution, clinical characteristics and mortality of candidaemia in a tertiary care university hospital in Turkey, 2007–2014. Mycoses 2017, 60, 433–439. [Google Scholar] [CrossRef] [PubMed]
  39. Muñoz, P.; Giannella, M.; Fanciulli, C.; Guinea, J.; Valerio, M.; Rojas, L. Candida tropicalis fungaemia: Incidence, risk factors and mortality in a general hospital. Clin. Microbiol Infect. 2011, 17, 1538–1545. [Google Scholar] [CrossRef] [Green Version]
  40. Almirante, B.; Rodríguez, D.; Park, B.J.; Cuenca-Estrella, M.; Planes, A.M.; Almela, M.; Jose, M.; Ferran, S.; Josefina, A.; Mont-serrat, G.; et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: Results from popula-tion-based surveillance, barcelona, Spain, from 2002 to 2003. Clin. Microbiol. Infect. 2005, 43, 35–1829. [Google Scholar] [CrossRef] [Green Version]
  41. Negri, M.; Silva, S.; Henriques, M.; Oliveira, R. Insights into Candida tropicalis nosocomial infections and virulence factors. Eur. J. Clin. Microbiol. Infect. Dis. 2011, 31, 1399–1412. [Google Scholar] [CrossRef] [Green Version]
  42. Vaquero-Herrero, M.P.; Ragozzino, S.; Castaño-Romero, F.; Siller-Ruiz, M.; González, R.S.; García-Sánchez, J.E.; García-García, I.; Marcos, M.; La Vega, H.G.T.-D. The Pitt Bacteremia Score, Charlson Comorbidity Index and Chronic Disease Score are useful tools for the prediction of mortality in patients with Candida bloodstream infection. Mycoses 2017, 60, 676–685. [Google Scholar] [CrossRef]
  43. Tumbarello, M.; Fiori, B.; Trecarichi, E.; Posteraro, P.; Losito, A.R.; De Luca, A.; Sanguinetti, M.; Fadda, G.; Cauda, R.; Posteraro, B. Risk Factors and Outcomes of Candidemia Caused by Biofilm-Forming Isolates in a Tertiary Care Hospital. PLoS ONE 2012, 7, e33705. [Google Scholar] [CrossRef] [Green Version]
  44. Da Silva, R.B.; Neves, R.P.; Hinrichsen, S.L.; de Lima-Neto, R.G. Candidemia in a public hospital in Northeastern Brazil: Epi-demiological features and risk factors in critically ill patients. Rev. Iberoam. Micol. 2019, 36, 181–185. [Google Scholar] [CrossRef]
  45. Muderris, T.; Kaya, S.; Ormen, B.; Gokmen, A.A.; Akpinar, C.V.; Gul, S.Y. Mortality and risk factor analysis for Candida blood stream infection: A three-year retrospective study. J. Mycol. Med. 2020, 30, 101008. [Google Scholar] [CrossRef] [PubMed]
  46. Zhang, W.; Song, X.; Wu, H.; Zheng, R. Epidemiology, risk factors and outcomes of Candida albicans vs. non- albicans candi-daemia in adult patients in Northeast China. Epidemiol. Infect. 2019, 147, e277. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Zhang, W.; Song, X.; Wu, H.; Zheng, R. Epidemiology, species distribution, and predictive factors for mortality of candidemia in adult surgical patients. BMC Infect. Dis. 2020, 20, 506. [Google Scholar] [CrossRef]
  48. Poves-Alvarez, R.; Cano-Hernández, B.; Muñoz-Moreno, M.F.; Balbás-Alvarez, S.; Román-García, P.; Gómez-Sánchez, E.; Martínez-Rafael, B.; Gómez-Pesquera, E.; Lorenzo-López, M.; Alvarez-Fuente, E.; et al. Impact of empirical treatment with antifungal agents on survival of patients with candidemia. Rev. Esp. Quim. Publ. Soc. Esp. Quim. 2019, 32, 6–14. [Google Scholar]
  49. Martinez, R.M.; Wolk, D.M. Bloodstream Infections. Microbiol. Spectr. 2016, 4, 4. [Google Scholar] [CrossRef] [Green Version]
  50. Nomellini, V.; Kaplan, L.J.; Sims, C.A.; Caldwell, C. Chronic Critical Illness and Persistent Inflammation: What can we Learn from the Elderly, Injured, Septic, and Malnourished? Shock 2018, 49, 4–14. [Google Scholar] [CrossRef]
  51. Reber, E.; Gomes, F.; Vasiloglou, M.F.; Schuetz, P.; Stanga, Z. Nutritional Risk Screening and Assessment. J. Clin. Med. 2019, 8, 1065. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Nutrients 13 03218 g001 550
Figure 1. Flow chart of patients with non-albicans candidemia included in the analysis.
Figure 1. Flow chart of patients with non-albicans candidemia included in the analysis.
Nutrients 13 03218 g001
Nutrients 13 03218 g002 550
Figure 2. Kaplan–Meier survival curve. Survival probability based on MUST score (≥2 vs. <2).
Figure 2. Kaplan–Meier survival curve. Survival probability based on MUST score (≥2 vs. <2).
Nutrients 13 03218 g002
Table
Table 1. Comparison of demographics and clinical characteristics of candidemic patients with MUST ≥ 2 and <2.
Table 1. Comparison of demographics and clinical characteristics of candidemic patients with MUST ≥ 2 and <2.
All, % MUST ≥ 2 MUST < 2 p
(n = 378)(n = 216)(n = 162)
Age66.13 ± 16.8865.76 ± 16.7966.63 ± 17.040.62
Gender (male)235 (62.2)137 (63.4)98 (60.5)0.560
Source of candidemia <0.001
 Primary89 (23.5)33 (15.3)56 (34.6)
 Central catheter100 (26.5)57 (26.4)43 (26.5)
 Urinary tract56 (14.8)38 (17.6)18 (11.1)
 Respiratory tract61 (16.1)39 (18.1)22 (16.2)
 Intra-abdomen65 (17.2)47 (21.8)18 (11.1)
 Wound 4 (1.1)1 (0.5)3 (1.9)
Candida species 0.01
 C. tropicalis146 (38.6)89 (41.2)57 (35.2)
 C. glabrata133 (35.2)82 (38.0)51 (31.5)
 C. parapsilosis78 (20.6)33 (15.3)45 (27.8)
 Others 21 (5.6)
Charlson comorbidity index4.23 ± 2.484.19 ± 2.474.29 ± 2.490.73
Candida colonization133 (35.2)84 (38.9)49 (30.2)0.08
Receiving chemotherapy106 (28.0)59 (27.3)47 (29.0)0.72
TPN use82 (21.7)57 (26.4)25 (15.4)0.01
Use of venous access267 (70.6)160 (74.1)107 (66.0)0.09
Foley use170 (45.0)100 (46.3)70 (43.2)0.55
Recent abdominal surgery63 (16.7)43 (19.9)20 (12.3)0.05
Use of steroids 309 (81.7)174 (80.6)135 (83.3)0.49
Concomitant bacterial infection179 (47.4)114 (52.8)65 (40.1)0.01
WBC (/µL) 0.35
 <6700125 (33.1)65 (30.1)60 (37.0)
 ≥6700 and < 12,100124 (32.8)73 (33.8)51 (31.5)
 ≥12,100129 (34.1)78 (36.1)51 (31.5)
Hb < 10 mg/dl209 (55.3)115 (53.2)94 (58.0)0.35
Platelet (/µL) 0.15
 <79,000133 (35.2)67 (31.0)66 (40.7)
 ≥79,000 and <185,000120 (31.7)73 (33.8)47 (29.0)
 ≥185,000125 (33.1)76 (35.2)49 (30.2)
ICU admission61 (15.1)39 (18.1)22 (13.6)0.24
BMI21.96 ± 4.5720.45 ± 4.4123.98 ± 3.98<0.001
Septic shock164 (43.4)106 (65.4)58 (35.8)0.01
Antifungal therapy 0.19
Initial use of fluconazole269 (71.2)157 (72.7)112 (69.1)
Initial use of echinocandin65 (17.2)31 (14.4)34 (21.0)
None44 (11.6)28 (12.3)16 (9.9)
Death within 28 days154 (40.7)97 (59.9)57 (35.2)0.06
Table
Table 2. In vitro susceptibility of antifungal agents among 304 non-albicans Candida isolates.
Table 2. In vitro susceptibility of antifungal agents among 304 non-albicans Candida isolates.
SpeciesAntifungal AgentMIC (mg/L)Susceptibility, No. (%)
RangeMIC50MIC90SSDDR (I + R)
C. tropicalisAnidulafungin 0.03–10.120.25142 (97.3)-3 (2.1)
(n = 146)Caspofungin 0.015–>80.120.25141 (96.6)-5 (3.4)
Micafungin 0.015–20.030.03142 (97.3)-4 (2.7)
Fluconazole 0.25–>25621694 (64.4)27 (18.5)25 (17.1)
Voriconazole 0.015–>80.25265 (44.5)59 (40.4)22 (15.1)
Itraconazole 0.06–10.250.5---
Posaconazole0.015–10.250.5---
Flucytosine≤0.06–>64≤0.060.12---
Amphotericin B≤0.12–20.51---
C. glabrataAnidulafungin 0.03–10.060.12109 (99.1)-1 (0.9)
(n = 110)Caspofungin 0.03–10.120.12101 (91.8) 9 (8.2)
Micafungin ≤0.008–10.0150.015108 (98.2) 2 (1.8)
Fluconazole 0.5–>2561632-106 (96.4)4 (3.6)
Voriconazole ≤0.008–40.50.5---
Itraconazole ≤0.015–40.51---
Posaconazole≤0.008–>812---
Flucytosine≤0.06–0.5 ≤0.06≤0.06---
Amphotericin B≤0.12–40.51---
C. parapsilosisAnidulafungin0.25–21248 (100)0 (0)0 (0)
(n = 48)Caspofungin 0.25–10.50.548 (100)0 (0)0 (0)
Micafungin 0.25–21248 (100)0 (0)0 (0)
Fluconazole 0.25–161245 (93.8)1 (2.1)2 (4.2)
Voriconazole ≤0.008–0.50.0150.0646 (95.8)1 (2.1)1 (2.1)
Itraconazole 0.03–10.120.12---
Posaconazole0.015–10.030.06---
Flucytosine≤0.06–0.50.120.25---
Amphotericin B≤0.12–10.50.5---
Table
Table 3. Predictors associated with 28-day mortality among patients with non-albicans candidemia.
Table 3. Predictors associated with 28-day mortality among patients with non-albicans candidemia.
VariablesUnadjusted HR p-ValueAdjusted HR p-Value
(95% CI) (95% CI)
Age1.00 (0.99–1.01)0.943
Gender, male 1.24 (0.89–1.73)0.208
Source of candidemia
 Primary Reference
 Central catheter2.35 (1.42–3.89)0.001
 Urinary tract1.10 (0.15–8.16)0.925
 Respiratory tract1.96 (1.10–3.50)0.022
 Intra-abdomen2.19 (1.26–3.81)0.005
 Wound 2.43 (1.43–4.12)0.001
Candida species
C. parapsilosis Reference Reference
 C. tropicalis2.36 (1.47–3.79)<0.0011.83 (1.12–2.97)0.015
 C. glabrata1.30 (0.79–2.16)0.3050.92 (0.55–1.56)0.766
 Others 1.20 (0.51–2.80)0.6811.09 (0.46–2.60)0.839
Charlson comorbidity index1.07 (1.00–1.14)0.0521.08 (1.01–1.16)0.020
Candida colonization1.38 (1.00–1.90)0.048
Receiving chemotherapy0.79 (0.55–1.15)0.222
TPN use0.93 (0.64–1.35)0.687
Use of venous access1.12 (0.79–1.60)0.535
Foley use1.65 (1.20–2.26)0.0021.67 (1.19–2.35)0.003
Recent abdominal surgery0.94 (0.62–1.43)0.775
Use of steroids 1.39 (0.88–2.20)0.161
Concomitant bacterial infection1.60 (1.16–2.20)0.0041.49 (1.06–2.08)0.021
WBC (/µL)
 <6700 Reference
 ≥6700 and <12,1000.74 (0.50–1.11)0.143
 ≥12,1000.93 (0.64–1.36)0.722
Hb <10 mg/dL1.54 (1.11–2.15)0.010
Platelet (/µL)
 <79,0003.70 (2.41–5.69)<0.0013.98 (2.56–6.19)<0.001
 ≥79,000 and <185,0001.72 (1.07–2.76)0.0251.58 (0.97–2.55)0.064
 ≥185,000 Reference Reference
ICU admission1.48 (1.01–2.18)0.045
BMI1.00(0.96–1.03)0.780
Septic shock2.06 (1.49–2.84)<0.001
Antifungal therapy
Initial use of fluconazole Reference Reference
Initial use of echinocandin1.02 (0.65–1.59)0.9271.02 (0.65–1.61)0.932
None4.94 (3.25–7.51)<0.0014.73 (3.07–7.29)<0.001
MUST ≥ 21.33 (0.96–1.85)0.0851.46 (1.03–2.07)0.034
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lee, Y.-C.; Chen, Y.-C.; Wang, J.-T.; Wang, F.-D.; Hsieh, M.-H.; Hii, I.-M.; Lee, Y.-L.; Ho, M.-W.; Liu, C.-E.; Chen, Y.-H.; et al. Impact of Nutritional Assessment on the Clinical Outcomes of Patients with Non-albicans Candidemia: A Multicenter Study. Nutrients 2021, 13, 3218. https://doi.org/10.3390/nu13093218

AMA Style

Lee Y-C, Chen Y-C, Wang J-T, Wang F-D, Hsieh M-H, Hii I-M, Lee Y-L, Ho M-W, Liu C-E, Chen Y-H, et al. Impact of Nutritional Assessment on the Clinical Outcomes of Patients with Non-albicans Candidemia: A Multicenter Study. Nutrients. 2021; 13(9):3218. https://doi.org/10.3390/nu13093218

Chicago/Turabian Style

Lee, Yi-Chien, Yong-Chen Chen, Jann-Tay Wang, Fu-Der Wang, Min-Han Hsieh, Ing-Moi Hii, Yu-Lin Lee, Mao-Wang Ho, Chun-Eng Liu, Yen-Hsu Chen, and et al. 2021. "Impact of Nutritional Assessment on the Clinical Outcomes of Patients with Non-albicans Candidemia: A Multicenter Study" Nutrients 13, no. 9: 3218. https://doi.org/10.3390/nu13093218

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop